Dhootapapeshwar Shoolavajrini Vati (60tab) : Indicated in Abdominal pain, digestive impairment, indigestion, vomiting.

64

About Dhootapapeshwar Shoolwarjini (Vajrini) Vati

Batch to batch performance and complete purity and safety are assured through the application of advanced pharmaceutical technology at every stage of manufacture. Dhooptapeshwar was founded in the pre-independence state of Maharastra and has made a name for itself as a unique product in the ayurveda market. ISO 9001: 2000 certification was given for the design, manufacture, and marketing of herbal health care products.

Abdominal pain, abdominal gas, and all types of colic can be effectively treated with the help of the herbal and mineral Ayurvedic medicine known as shoolwarjini bati.

Shoolwarjini bati strengthens the digestive system and aids in toxin removal from the body.

Ingredients of Dhootapapeshwar Shoolwarjini (Vajrini) Vati

Kajjali

Bhasma Lauh

Hing

Tankan

Trikatu

Trifhala

Jaiphal

Bhasma Shankha

Indications of Dhootapapeshwar Shoolwarjini (Vajrini) Vati

stomach ache

Gulma

the spleen growing larger

abdominal gas that is too much

Colic of all kinds

Dosage of Dhootapapeshwar Shoolwarjini (Vajrini) Vati

Once or twice a day, one to two tabs with water.

Precautions of Dhootapapeshwar Shoolwarjini (Vajrini) Vati

1. Keep kids out of your sight and out of your reach.

2. Due to its potency, it should be used with caution by those who have Pitta roga, hyperacidity, bleeding disorders, or ulcers.

3. It acts as an emmenagogue; use during pregnancy is not advised.

5. It contains jaggery, making it unsuitable for diabetics, and should only be taken in the recommended doses because high doses vitiate all doshas and cause burning sensations.

  1. Self-medication is not advised.

Terms and Conditions

Before purchasing this medication, we have assumed that you sought medical advice and are not using it for self-medication.

Attributes
BrandDhootapapeshwar
Remedy TypeAyurvedic
Country of OriginIndia
Form FactorTablet
Price₹ 135

Comments are closed.